| Pharmaceutical Information |
| Drug Name |
Thalidomide |
| Drug ID |
BADD_D02192 |
| Description |
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem] |
| Indications and Usage |
For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. |
| Marketing Status |
Prescription |
| ATC Code |
L04AX02 |
| DrugBank ID |
DB01041
|
| KEGG ID |
D00754
|
| MeSH ID |
D013792
|
| PubChem ID |
5426
|
| TTD Drug ID |
D0U7GK
|
| NDC Product Code |
59572-205; 59572-210; 59572-220; 59572-215; 69988-0052; 63818-0424; 17337-0301; 68554-0011 |
| Synonyms |
Thalidomide | Sedoval | Thalomid |
|
| Chemical Information |
| Molecular Formula |
C13H10N2O4 |
| CAS Registry Number |
50-35-1 |
| SMILES |
C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
|
|
| ADRs Induced by Drug |
|
|
